$BIXT
BIOXYTRAN, INC Stock $bixt

$bixt Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022572 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	-$490.1K	$494.1K	$579.0K
YoY Change	-234.17%	52.65%	-56.85%
% of Gross Profit
Research & Development	$475.9K	$43.14K	$240.1K
YoY Change	161.53%	-94.0%	-30.8%
% of Gross Profit
Depreciation & Amortization	$910.00	$1.820K
YoY Change
% of Gross Profit
Operating Expenses	-$14.23K	$537.2K	$819.1K
YoY Change	-102.6%	-48.46%	-51.5%
Operating Profit	$14.23K	-$537.2K	-$819.1K
YoY Change	-102.6%	-48.46%
Interest Expense	-$216.5K	-$96.82K	-$144.3K
YoY Change	246.67%	-4.44%	65.06%
% of Operating Profit	-1521.69%
Other Income/Expense, Net	-$217.4K	-$96.82K	-$144.3K
YoY Change	248.14%	-4.45%
Pretax Income	-$203.1K	-$634.0K	-$963.4K
YoY Change	-66.68%	-44.56%	-45.76%
Income Tax
% Of Pretax Income
Net Earnings	-$123.6K	-$622.3K	-$912.3K
YoY Change	-73.98%	-30.6%	-43.75%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00	-$0.01	-$0.01
Diluted Earnings Per Share	-$1.062K	-$5.615K	-$8.230K
COMMON SHARES
Basic Shares Outstanding	111.5M shares	110.8M shares	110.8M shares
Diluted Shares Outstanding	116.4M shares	110.8M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$374.2K	$500.7K	$739.6K
YoY Change	53.36%	29.03%	707.05%
Cash & Equivalents	$374.2K	$500.7K	$739.6K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$374.2K	$500.7K	$739.6K
YoY Change	-49.66%	-43.58%	101.88%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$74.35K	$67.55K	$68.35K
YoY Change	292.14%	256.27%	260.69%
TOTAL ASSETS
Total Short-Term Assets	$374.2K	$500.7K	$739.6K
Total Long-Term Assets	$74.35K	$67.55K	$68.35K
Total Assets	$448.5K	$568.2K	$807.9K
YoY Change	-41.16%	-37.3%	109.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$341.5K	$1.062M	$796.5K
YoY Change	0.79%		116.23%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$2.158M	$3.594M	$3.552M
YoY Change	3.12%	74.26%	74.72%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.998M	$5.329M	$4.887M
YoY Change	11.88%	140.73%	69.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.998M	$5.329M	$4.887M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.998M	$5.329M	$4.439M
YoY Change	-17.46%	61.45%	9.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.41M	-$10.29M	-$9.666M
YoY Change	34.95%	42.1%
Common Stock	$123.0K	$110.8K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.010M	-$4.761M	-$4.079M
YoY Change
Total Liabilities & Shareholders Equity	$448.5K	$568.2K	$807.9K
YoY Change	-41.16%	-37.3%	109.69%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$123.6K	-$622.3K	-$912.3K
YoY Change	-73.98%	-30.6%	-43.75%
Depreciation, Depletion And Amortization	$910.00	$1.820K
YoY Change
Cash From Operating Activities	-$718.8K	-$238.8K	-$691.4K
YoY Change	398.98%	-76.56%	76.79%
INVESTING ACTIVITIES
Capital Expenditures	-$7.710K	-$120.00	-$22.32K
YoY Change			149.39%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$7.710K	-$120.00	-$22.32K
YoY Change			149.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	600.0K	0.000	1.381M
YoY Change		-100.0%	206.88%
NET CHANGE
Cash From Operating Activities	-718.8K	-238.8K	-691.4K
Cash From Investing Activities	-7.710K	-120.0	-22.32K
Cash From Financing Activities	600.0K	0.000	1.381M
Net Change In Cash	-126.5K	-238.9K	667.2K
YoY Change	-12.19%	-180.6%	1235.8%
FREE CASH FLOW
Cash From Operating Activities	-$718.8K	-$238.8K	-$691.4K
Capital Expenditures	-$7.710K	-$120.00	-$22.32K
Free Cash Flow	-$711.1K	-$238.7K	-$669.1K
YoY Change	393.63%	-76.57%	75.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent		usd
CY2021Q4	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm2
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	dei	Entity Central Index Key EntityCentralIndexKey	0001445815
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent		usd
CY2021Q4	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent		usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	BIXT	Non Cash Forfeiture Of Stock Options NonCashForfeitureOfStockOptions		usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
	BIXT	Forgiveness Of Related Party Debt Recorded To Additional Paidin Capital ForgivenessOfRelatedPartyDebtRecordedToAdditionalPaidinCapital		usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35027
	dei	Entity Registrant Name EntityRegistrantName	BIOXYTRAN, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2797630
	dei	Entity Address Address Line1 EntityAddressAddressLine1	75 2nd Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste 605
	dei	Entity Address City Or Town EntityAddressCityOrTown	Needham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02494
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	454-1199
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	264060	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	111496166	shares
CY2022Q2	us-gaap	Cash Cash	500677	usd
CY2021Q4	us-gaap	Cash Cash	72358	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	500677	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	72358	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	67548	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46932	usd
CY2022Q2	us-gaap	Assets Assets	568225	usd
CY2021Q4	us-gaap	Assets Assets	119290	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	556835	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	624316	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1062000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	531000	usd
CY2022Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	60150	usd
CY2022Q2	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent	56240	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3593650	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2122181	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5328875	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3277497	usd
CY2022Q2	us-gaap	Liabilities Liabilities	5328875	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3277497	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110840998	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110840998	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110840998	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110840998	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	110841	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	110841	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5876859	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5881876	usd
CY2022Q2	BIXT	Noncontrolling Interest NoncontrollingInterest	-460063	usd
CY2021Q4	BIXT	Noncontrolling Interest NoncontrollingInterest	-397256	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10288287	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8753668	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-4760650	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3158207	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	568225	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119290	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43141	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	718652	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	283266	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1065685	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	447360	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	272614	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1003941	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	839934	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	46723	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	51050	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	69123	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	825608	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	537224	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1042316	usd
	us-gaap	Operating Expenses OperatingExpenses	1356330	usd
	us-gaap	Operating Expenses OperatingExpenses	2731227	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-537224	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1042316	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1356330	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2731227	usd
CY2022Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	54480	usd
CY2021Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	84217	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	106515	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	171627	usd
CY2022Q2	BIXT	Debt Discount And Intangible Amortization DebtDiscountAndIntangibleAmortization	42336	usd
CY2021Q2	BIXT	Debt Discount And Intangible Amortization DebtDiscountAndIntangibleAmortization	17103	usd
	BIXT	Debt Discount And Intangible Amortization DebtDiscountAndIntangibleAmortization	134581	usd
	BIXT	Debt Discount And Intangible Amortization DebtDiscountAndIntangibleAmortization	17103	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-96816	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-101320	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-241096	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-188730	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-634040	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1143636	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1597426	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2919957	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-634040	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-1143636	usd
	us-gaap	Profit Loss ProfitLoss	-1597426	usd
	us-gaap	Profit Loss ProfitLoss	-2919957	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11691	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-246935	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-62807	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-401549	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-622349	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-896701	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1534619	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2518408	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110840998	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103371579	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110840998	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101753891	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1941256	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	6750	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	328032	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	439776	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	450000	usd
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-154614	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1621707	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-2493019	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	7650	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15300	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15300	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	27650	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	27650	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	986864	usd
CY2021Q2	BIXT	Stock Issued During Period Value For Conversion Of Debt StockIssuedDuringPeriodValueForConversionOfDebt	121042	usd
CY2021Q2	BIXT	Adjustments To Additional Paid In Capital Forgiveness Of Related Party AdjustmentsToAdditionalPaidInCapitalForgivenessOfRelatedParty	1020323	usd
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	450	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	150000	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-246935	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-896701	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1307376	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3158207	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	42250	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-51116	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-912270	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4079343	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4079343	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-47267	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11691	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-622349	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-4760650	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-4760650	usd
	us-gaap	Profit Loss ProfitLoss	-1597426	usd
	us-gaap	Profit Loss ProfitLoss	-2919957	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	132759	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17103	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1822	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	69123	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	825608	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	224586	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-67481	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	217851	usd
	BIXT	Increase Decrease Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseAccountsPayableAndAccruedExpensesRelatedParty	531000	usd
	BIXT	Increase Decrease Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseAccountsPayableAndAccruedExpensesRelatedParty	674290	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-930203	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1409691	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22438	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8954	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22438	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8954	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	600000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1380960	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1165000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1380960	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1765000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	428319	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	346355	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	72358	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41688	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	500677	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	388043	usd
	us-gaap	Interest Paid Net InterestPaidNet	69900	usd
	us-gaap	Stock Issued1 StockIssued1	42250	usd
	BIXT	Non Cash Forfeiture Of Stock Options NonCashForfeitureOfStockOptions	47267	usd
	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote	86040	usd
	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote	102747	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1107906	usd
	BIXT	Forgiveness Of Related Party Debt Recorded To Additional Paidin Capital ForgivenessOfRelatedPartyDebtRecordedToAdditionalPaidinCapital	1020323	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1380960	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1165000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	600000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zKfJkyCCNwr9" style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	46932	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1822	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	283266	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1065685	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	264060	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.25
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	67548	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46932	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1062000	usd
CY2022Q2	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent	56240	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	531000	usd
CY2022Q2	us-gaap	Cash Cash	500677	usd
CY2022Q2	BIXT	Working Capital WorkingCapital	-4828198	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10288287	usd
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	69370	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	121893	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	375371	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2310	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	122300	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	85685	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	47832	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	32010	usd
CY2022Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	262500	usd
CY2021Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	131250	usd
CY2022Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	60150	usd
CY2022Q2	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent	56240	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3593650	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2122181	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5328875	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3277497	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3632000	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	122300	usd
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	3754300	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2165000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	85685	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2250685	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3632000	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2165000	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	38350	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	42819	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3593650	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2122181	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110840998	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110840998	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110840998	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110840998	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	272000	shares
CY2020Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.00
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	272000	shares
CY2021Q2	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.00
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 End SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2End	P3Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	272000	shares
CY2021Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.00
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	264060	shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.25
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm2	P5Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	536060	shares
CY2022Q2	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.14
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 End SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2End	P3Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.25
	BIXT	Warrants Exercisable Weighted Average Remaining Contractual Term WarrantsExercisableWeightedAverageRemainingContractualTerm	P3Y6M
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable	18484	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.6118	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	48000	shares
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	620000	shares
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.50
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P0Y9M14D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	62760	usd
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	620000	shares
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.50
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P0Y9M14D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	62760	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y9M14D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	62760	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd

Files In Submission

Name	View Source	Status
0001493152-22-022572-index-headers.html	Edgar Link	pending
0001493152-22-022572-index.html	Edgar Link	pending
0001493152-22-022572.txt	Edgar Link	pending
0001493152-22-022572-xbrl.zip	Edgar Link	pending
bixt-20220630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
bixt-20220630_def.xml	Edgar Link	unprocessable
bixt-20220630_lab.xml	Edgar Link	unprocessable
bixt-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bixt-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIXT
BIOXYTRAN, INC Stock $bixt

2022 Q3 Form 10-Q Financial Statement

#000149315222022572 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT BIOXYTRAN, INC Stock $bixt

2022 Q3 Form 10-Q Financial Statement

#000149315222022572 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT
BIOXYTRAN, INC Stock $bixt